Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India

Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis, by Raphael B. Stricker, MD,1 Melissa C. Fesler, FNP-BC1
Abstract: To date, the COVID-19 pandemic has resulted in more than 200 million cases of SARS-CoV-2 infection and more than four million deaths world-wide. Although novel COVID-19 vaccines have become clinically available, the safety and efficacy of these vaccines remains open to question. Alternate approaches to prevention of disease have received little attention, and one medication, hydroxychloroquine (HCQ), has been attacked and dismissed based on flawed studies and political controversy that obscured the value of this treatment as pre-exposure prophylaxis (PrEP) for SARS-CoV-2 infection.

Original paper:
R.B. Stricker and M.C. Fesler. "Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis", Journal of Infection and Public Health 14 (2021), 1161-1163
https://doi.org/10.1016/j.jiph.2021.08.001

Additional papers on HCQ PrEP:
M.C Fesler and R.B. Stricker. "Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women", International Journal of General Medicine 14 (2021), 279-284
https://doi.org/10.2147/IJGM.S295627
R.B. Stricker and M.C. Fesler. "Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19", Infection and Drug Resistance 13 (2020), 3689-3694
https://doi.org/10.2147/IDR.S264831

Help Dr Peter McCullough with legal, IT, and travel costs. Donate here:
https://givesendgo.com/G2DR5